// App-Quantinova.ai

DXT42 : Rationale and Design of Classic-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets

Researchers

Presenter

  • Alexey Boyko

Principal Investigators

  • Jorge Correale

  • Gilles Edan

  • Mark S. Freedman

  • Gavin Giovannoni

  • Xavier Montalban

  • Kottil Rammohan

  • Thomas P. Leist

  • Dusan Stefoski

  • Bassem Yamout

  • Belen Garcia-Alonso

  • Aida Aydemir

  • Elisabetta Verdun di Cantogno

Medical Centers

  • Pirogov Russian National Research Medical University, Moscow, Russia

  • University of Ottawa and the Ottawa Hospital Research Institute

  • Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron St Michael's Hospital, University of Toronto

  • Multiple Sclerosis Center, University of Miami, Miami, FL

  • Jefferson University Hospital,

  • University Hospital of Berne,

  • Wah Medical College

  • Queen Mary University, London, UK

  • Neurology, American University of Beirut Medical Center

Locations

  • United Kingdom

  • Palestine

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Placebo Control

  • Prospective

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved